Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Next steps for belzutifan for Von Hippel-Lindau syndrome

Ramaprasad Srinivasan • 17 Jun 2022
ASCO 2022
Genitourinary Cancer Kidney Cancer Belzutifan

Ramaprasad Srinivasan, MD, PhD, National Cancer Institute, Bethesda, MD, discusses the potential of belzutifan for patients with Von Hippel-Lindau syndrome, and the next steps in investigating how this drug could benefit these patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Ramaprasad Srinivasan

4:12
Kidney cancer at ESMO 2022: KEYNOTE-564 and PROSPER
Ramaprasad Srinivasan • 20 Sep 2022
4:44
Pathophysiology and management of Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 20 Sep 2022
2:32
Unanswered questions of interest from the LITESPARK-004 trial
Ramaprasad Srinivasan • 20 Sep 2022
9:35
LITESPARK-004: 36 month follow-up of belzutifan in Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 20 Sep 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals